Immunotherapy advances include early clinical success with Genmab and AbbVie's T cell engager Epkinly showing promise for follicular lymphoma patients, and oncolytics and bispecific antibodies gaining momentum. Research highlights molecular drivers of tumor immune evasion such as nociceptor-infiltrating immune suppression and bone metastases fostering immature immune cells, which undermine therapy effectiveness. Additionally, antibody-drug conjugates continue facing challenges in target selection and side effect management, driving innovation in next-generation modalities.